Response to Comments: MolDX: VitaRisk ™ Pharmacogenetic Test for Dry Age-related Macular Degeneration (AMD)

This document (A55564) is an administrative response to comments on the MolDX VitaRisk pharmacogenetic test for dry age-related macular degeneration (LCD DL37140). It records the comment period (02/16/2017–04/03/2017), notice period (05/25/2017–07/09/2017), and that the LCD became final on 07/10/2017. The document contains no clinical coverage criteria, limitations, documentation requirements for claims, or frequency limits.